-
1
-
-
84923775846
-
Burden of Clostridium difficile infection in the United States
-
Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372:825-34.
-
(2015)
N Engl J Med
, vol.372
, pp. 825-834
-
-
Lessa, F.C.1
Mu, Y.2
Bamberg, W.M.3
-
2
-
-
79551527297
-
Fidaxomicin versus vancomycin for Clostridium difficile infection
-
Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422-31.
-
(2011)
N Engl J Med
, vol.364
, pp. 422-431
-
-
Louie, T.J.1
Miller, M.A.2
Mullane, K.M.3
-
3
-
-
19344363493
-
Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec Canada
-
Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40:1591-7.
-
(2005)
Clin Infect Dis
, vol.40
, pp. 1591-1597
-
-
Pepin, J.1
Alary, M.E.2
Valiquette, L.3
-
4
-
-
20444486921
-
Treatment of recurrent Clostridium difficile-associated disease
-
Surawicz CM. Treatment of recurrent Clostridium difficile-associated disease. Nat Clin Pract Gastroenterol Hepatol 2004; 1:32-8.
-
(2004)
Nat Clin Pract Gastroenterol Hepatol
, vol.1
, pp. 32-38
-
-
Surawicz, C.M.1
-
5
-
-
84960113829
-
Clinical and healthcare burden of multiple recurrences of Clostridium difficile infection
-
Sheitoyan-Pesant C, Abou Chakra CN, Pepin J, Marcil-Heguy A, Nault V, Valiquette L. Clinical and healthcare burden of multiple recurrences of Clostridium difficile infection. Clin Infect Dis 2016; 62:574-80.
-
(2016)
Clin Infect Dis
, vol.62
, pp. 574-580
-
-
Sheitoyan-Pesant, C.1
Abou Chakra, C.N.2
Pepin, J.3
Marcil-Heguy, A.4
Nault, V.5
Valiquette, L.6
-
6
-
-
84953345711
-
Fecal microbiota transplantation for the treatment of Clostridium difficile infection
-
Rao K, Safdar N. Fecal microbiota transplantation for the treatment of Clostridium difficile infection. J Hosp Med 2015; 11:56-61.
-
(2015)
J Hosp Med
, vol.11
, pp. 56-61
-
-
Rao, K.1
Safdar, N.2
-
7
-
-
35348991541
-
Changing epidemiology of Clostridium difficile-associated disease in children
-
Benson L, Song X, Campos J, Singh N. Changing epidemiology of Clostridium difficile-associated disease in children. Infect Control Hosp Epidemiol 2007; 28:1233-5.
-
(2007)
Infect Control Hosp Epidemiol
, vol.28
, pp. 1233-1235
-
-
Benson, L.1
Song, X.2
Campos, J.3
Singh, N.4
-
8
-
-
41649114003
-
Surveillance for community-associated Clostridium difficile-Connecticut, 2006
-
Centers for Disease Control
-
Centers for Disease Control. Surveillance for community-associated Clostridium difficile-Connecticut, 2006. MMWR Morb Mortal Wkly Rep 2008; 57:340-3.
-
(2008)
MMWR Morb Mortal Wkly Rep
, vol.57
, pp. 340-343
-
-
-
9
-
-
77957882527
-
Multicenter study of Clostridium difficile infection rates from 2000 to 2006
-
Dubberke ER, Butler AM, Yokoe DS, et al. Multicenter study of Clostridium difficile infection rates from 2000 to 2006. Infect Control Hosp Epidemiol 2010; 31:1030-7.
-
(2010)
Infect Control Hosp Epidemiol
, vol.31
, pp. 1030-1037
-
-
Dubberke, E.R.1
Butler, A.M.2
Yokoe, D.S.3
-
11
-
-
84867484557
-
Burden of Clostridium difficile infection in longterm care facilities in Monroe County New York
-
Pawar D, Tsay R, Nelson DS, et al. Burden of Clostridium difficile infection in longterm care facilities in Monroe County, New York. Infect Control Hosp Epidemiol 2012; 33:1107-12.
-
(2012)
Infect Control Hosp Epidemiol
, vol.33
, pp. 1107-1112
-
-
Pawar, D.1
Tsay, R.2
Nelson, D.S.3
-
12
-
-
79958761012
-
Using electronic health information to risk-stratify rates of Clostridium difficile infection in US hospitals
-
Zilberberg MD, Tabak YP, Sievert DM, et al. Using electronic health information to risk-stratify rates of Clostridium difficile infection in US hospitals. Infect Control Hosp Epidemiol 2011; 32:649-55.
-
(2011)
Infect Control Hosp Epidemiol
, vol.32
, pp. 649-655
-
-
Zilberberg, M.D.1
Tabak, Y.P.2
Sievert, D.M.3
-
13
-
-
56249107224
-
Meta-analysis to assess risk factors for recurrent Clostridium difficile infection
-
Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 2008; 70:298-304.
-
(2008)
J Hosp Infect
, vol.70
, pp. 298-304
-
-
Garey, K.W.1
Sethi, S.2
Yadav, Y.3
Dupont, H.L.4
-
14
-
-
74249096590
-
Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI)
-
Leav BA, Blair B, Leney M, et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2010; 28:965-9.
-
(2010)
Vaccine
, vol.28
, pp. 965-969
-
-
Leav, B.A.1
Blair, B.2
Leney, M.3
-
15
-
-
74849098405
-
Treatment with monoclonal antibodies against Clostridium difficile toxins
-
Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362:197-205.
-
(2010)
N Engl J Med
, vol.362
, pp. 197-205
-
-
Lowy, I.1
Molrine, D.C.2
Leav, B.A.3
-
16
-
-
0028972348
-
Increased risk of diarrhoea caused by Clostridium difficile in elderly patients receiving cefotaxime
-
Impallomeni M, Galletly NP, Wort SJ, Starr JM, Rogers TR. Increased risk of diarrhoea caused by Clostridium difficile in elderly patients receiving cefotaxime. BMJ 1995; 311:1345-6.
-
(1995)
BMJ
, vol.311
, pp. 1345-1346
-
-
Impallomeni, M.1
Galletly, N.P.2
Wort, S.J.3
Starr, J.M.4
Rogers, T.R.5
-
17
-
-
84899796356
-
Risk estimation for recurrent Clostridium difficile infection based on clinical factors
-
D'Agostino RB Sr, Collins SH, Pencina KM, Kean Y, Gorbach S. Risk estimation for recurrent Clostridium difficile infection based on clinical factors. Clin Infect Dis 2014; 58:1386-93.
-
(2014)
Clin Infect Dis
, vol.58
, pp. 1386-1393
-
-
D'Agostino, Sr.R.B.1
Collins, S.H.2
Pencina, K.M.3
Kean, Y.4
Gorbach, S.5
-
18
-
-
79952588451
-
Development and validation of a Clostridium difficile infection risk prediction model
-
Dubberke ER, Yan Y, Reske KA, et al. Development and validation of a Clostridium difficile infection risk prediction model. Infect Control Hosp Epidemiol 2011; 32:360-6.
-
(2011)
Infect Control Hosp Epidemiol
, vol.32
, pp. 360-366
-
-
Dubberke, E.R.1
Yan, Y.2
Reske, K.A.3
-
19
-
-
84863651274
-
Predictors of first recurrence of Clostridium difficile infection: Implications for initial management
-
Eyre DW, Walker AS, Wyllie D, et al. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis 2012; 55: S77-87.
-
(2012)
Clin Infect Dis
, vol.55
, pp. S77-S87
-
-
Eyre, D.W.1
Walker, A.S.2
Wyllie, D.3
-
20
-
-
84903755337
-
Development and validation of a recurrent Clostridium difficile risk-prediction model
-
Zilberberg MD, Reske K, Olsen M, Yan Y, Dubberke ER. Development and validation of a recurrent Clostridium difficile risk-prediction model. J Hosp Med 2014; 9:418-23.
-
(2014)
J Hosp Med
, vol.9
, pp. 418-423
-
-
Zilberberg, M.D.1
Reske, K.2
Olsen, M.3
Yan, Y.4
Dubberke, E.R.5
-
21
-
-
0035915688
-
Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea
-
Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357:189-93.
-
(2001)
Lancet
, vol.357
, pp. 189-193
-
-
Kyne, L.1
Warny, M.2
Qamar, A.3
Kelly, C.P.4
-
22
-
-
0036467063
-
Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile
-
Kyne L, Hamel MB, Polavaram R, Kelly CNP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002; 34:346-53.
-
(2002)
Clin Infect Dis
, vol.34
, pp. 346-353
-
-
Kyne, L.1
Hamel, M.B.2
Polavaram, R.3
Kelly, C.N.P.4
-
23
-
-
0028089161
-
Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection
-
Warny M, Vaerman JP, Avesani V, Delmee M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 1994; 62:384-9.
-
(1994)
Infect Immun
, vol.62
, pp. 384-389
-
-
Warny, M.1
Vaerman, J.P.2
Avesani, V.3
Delmee, M.4
-
24
-
-
77957988127
-
The role of toxin A and toxin B in Clostridium difficile infection
-
Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. The role of toxin A and toxin B in Clostridium difficile infection. Nature 2010; 467:711-3.
-
(2010)
Nature
, vol.467
, pp. 711-713
-
-
Kuehne, S.A.1
Cartman, S.T.2
Heap, J.T.3
Kelly, M.L.4
Cockayne, A.5
Minton, N.P.6
-
25
-
-
67349114409
-
Toxin B is essential for virulence of Clostridium difficile
-
Lyras D, O'Connor JR, Howarth PM, et al. Toxin B is essential for virulence of Clostridium difficile. Nature 2009; 458:1176-9.
-
(2009)
Nature
, vol.458
, pp. 1176-1179
-
-
Lyras, D.1
O'Connor, J.R.2
Howarth, P.M.3
-
26
-
-
80455173556
-
Host and pathogen factors for Clostridium difficile infection and colonization
-
Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011; 365:1693-703.
-
(2011)
N Engl J Med
, vol.365
, pp. 1693-1703
-
-
Loo, V.G.1
Bourgault, A.M.2
Poirier, L.3
-
27
-
-
84871775506
-
Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease
-
Steele J, Mukherjee J, Parry N, Tzipori S. Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. J Infect Dis 2013; 207:323-30.
-
(2013)
J Infect Dis
, vol.207
, pp. 323-330
-
-
Steele, J.1
Mukherjee, J.2
Parry, N.3
Tzipori, S.4
-
28
-
-
84995491044
-
Phase 3 double-blind study of bezlotoxumab alone and with actoxumab for prevention of recurrent C. Difficile infection in patients on standard of care antibiotics (MODIFY II)
-
San Diego, CA September
-
Gerding D, Wilcox M, Poxton I, et al. Phase 3 double-blind study of bezlotoxumab alone and with actoxumab for prevention of recurrent C. difficile infection in patients on standard of care antibiotics (MODIFY II). In: Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and 28th International Congress of Chemotherapy (ICC) meeting, San Diego, CA, 17-21 September 2015.
-
(2015)
Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and 28th International Congress of Chemotherapy (ICC) Meeting
, pp. 17-21
-
-
Gerding, D.1
Wilcox, M.2
Poxton, I.3
-
29
-
-
84995491044
-
Phase 3 double-blind study of actoxumab (ACT) & bezlotoxumab (BEZ) for prevention of recurrent C. Difficile infection (rCDI) in patients on standard of care (SoC) antibiotics (MODIFY I)
-
San Diego, CA September
-
Wilcox M, Gerding D, Poxton I, et al. Phase 3 double-blind study of actoxumab (ACT) & bezlotoxumab (BEZ) for prevention of recurrent C. difficile infection (rCDI) in patients on standard of care (SoC) antibiotics (MODIFY I). In: Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and 28th International Congress of Chemotherapy (ICC) meeting, San Diego, CA, 17-21 September 2015.
-
(2015)
Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and 28th International Congress of Chemotherapy (ICC) Meeting
, pp. 17-21
-
-
Wilcox, M.1
Gerding, D.2
Poxton, I.3
|